Clinical Trial

Residual Neuromuscular Block in the Post-Anesthetic Unit and Postoperative Complications

Study acronym: Porcerito
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 24, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The use of neuromuscular blockers (NMB) is essential to optimize surgical conditions, ensure patient immobility during the intervention and prevent complications derived from involuntary movements. Intraoperative monitoring of neuromuscular relaxation allows the depth of neuromuscular blockade to be accurately evaluated, guaranteeing ideal conditions for the surgical team. Residual neuromuscular blockade (RNMB) is the persistence of muscle paralysis after the administration of NMB during a surgical intervention. The appearance of RNMB poses substantial challenges in the postoperative period, as it has negative repercussions for the safety and well-being of the patient.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-23; most recent amendment 2025-08-19.
Status change: Not Yet Recruiting → Recruiting 2024-07-23
Trial Details
NCT Number NCT06386354
Lead Sponsor Hospital Universitario de Gran Canaria Doctor Negrín
Conditions Postoperative Neuromuscular Block, Postoperative Complications
Enrollment 296 participants
Start Date 2024-05-01
Primary Completion 2025-10-30 (estimated)
Study Completion 2025-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-24